You are here

Dr Stephen Wren

Dr Stephen P Wren is highly experienced in medicinal chemistry and has worked on a diverse set of biological targets over many disease areas in several organisations (Xenova, Argenta Discovery and Summit plc). He has an extensive track record in project and team management, intellectual property, drug discovery in many therapeutic areas and helped lead  the chemistry effort directed towards the identification of SMTC1100 (Summit’s Duchenne Muscular Dystrophy drug, currently undergoing clinical evaluation).

Dr Wren currently conducts research at the Alzheimer’s Research UK Oxford Drug Discovery Institute. This combines the deep disease knowledge and biology expertise of  the University of Oxford with high quality, innovative drug discovery technologies.

"We couple sophisticated drug discovery capabilities with deep disease-specific expertise in genetics and molecular biology throughout the University and beyond, to identify new ways of treating neurodegeneration. We have the knowledge, resources and drive to create lead compounds for neurodegenerative targets and will work closely with industrial partners and private/public funding agencies to ensure successful candidates continue through the drug discovery pipeline towards commercialisation.

The Oxford Drug Discovery Institute has expertise in Imaging, Compound Screening, Medicinal Chemistry, Target Development and Drug Discovery.

We work alongside of several university partners including the Departments of Psychiatry, Chemistry, Physiology, Anatomy and Genetics, the Structural Genomics Consortium, the Nuffield Department of Clinical Neurosciences and the Weatherall Institute of Molecular Medicine (John Radcliffe Hospital) to advance our projects.

I use my medicinal chemistry experience to help develop novel treatments for dementia. This involves the design and preparation of potential drugs with certain properties that allow entry into the brain (central nervous system)."

Dr Stephen Wren and Dr Linda Troeberg have been awarded funding by St Hilda's College Research Committee to support cross-disciplinary research between their groups at the Target Discovery Institute and the Kennedy Institute of Rheumatology respectively. This will take the form of a laboratory-based study to investigate potential novel agents to treat osteoarthritis. Lucy Britton, a second year St Hilda’s Biochemistry student, has been selected for the internship, and will join their groups for eight weeks in the summer of 2017.